<DOC>
	<DOCNO>NCT01072539</DOCNO>
	<brief_summary>The primary objective study identify change safety profile adverse event serious adverse event . And secondary objective evaluate clinical response clinically evaluable population test-of cure ( TOC ) end treatment ( EOT ) assessment , microbiologic response subject level , available .</brief_summary>
	<brief_title>Study Evaluating The Safety And Effectiveness In Subjects With Tigecycline Treatment</brief_title>
	<detailed_description>Prior conduct study , investigator explain study objective , etc prospective subject basis `` explanatory material . '' The informed consent obtain write form subject voluntarily .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Bacterial</mesh_term>
	<mesh_term>Intraabdominal Infections</mesh_term>
	<mesh_term>Tigecycline</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>Evidence personally sign date informed consent document indicate subject ( legal representative ) inform pertinent aspect study . Subjects must meet follow inclusion criterion eligible enrollment study : Adults 18 year age old , one following : Complicated skin skin structure infection Complicated intraabdominal infection Communityacquired bacterial pneumonia Subjects present follow include study : Patients know hypersensitivity tigecycline Patients rare hereditary problem galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>infection</keyword>
	<keyword>Tygacil</keyword>
	<keyword>PMS</keyword>
</DOC>